1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-8.57%
Cash & equivalents declining -8.57% while Biotechnology shows -8.73% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
No Data
No Data available this quarter, please select a different quarter.
-8.57%
Near the Biotechnology median of -8.35% for total liquid asset growth. Charlie Munger would check if this is standard for the industry cycle.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-16.59%
Exceeding 1.5x Biotechnology median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
-8.67%
1.25-1.5x the Biotechnology median of -7.26%. Mohnish Pabrai would examine if this advantage is strategic or idle cash buildup.
-8.20%
PP&E growth ≥ 1.5x the Biotechnology median of -4.13%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.26%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
-7.12%
≥ 1.5x the Biotechnology median of -2.46%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
No Data
No Data available this quarter, please select a different quarter.
-8.62%
1.25-1.5x Biotechnology median of -5.93%. Mohnish Pabrai might see above-average growth. Check if financed sensibly.
-100.00%
Payables growth above 1.5x Biotechnology median of -0.37%. Jim Chanos might see a warning sign of stressed supplier payments.
-100.00%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1405.81%
Above 1.5x Biotechnology median of 2.93%. Jim Chanos suspects a potential short-term burden spike.
-20.28%
Below half Biotechnology median of 3.00%. Joel Greenblatt sees more conservative short-term leverage than peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.40%
Below half Biotechnology median of -1.77%. Joel Greenblatt sees more conservative long-term liability expansion vs. peers.
No Data
No Data available this quarter, please select a different quarter.
-4.61%
Below half Biotechnology median of 0.01%. Joel Greenblatt sees a much lower liability expansion vs. peers.
No Data
No Data available this quarter, please select a different quarter.
-3.23%
0.75-0.9x Biotechnology median of -3.75%. John Neff wonders if the firm lags peers in reinvested profits.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-12.84%
≥ 1.5x Biotechnology median of -7.77%. Joel Greenblatt sees stronger equity growth vs. peers.
-8.62%
1.25-1.5x Biotechnology median of -5.98%. Mohnish Pabrai notes above-average growth in liabilities + equity.
-100.00%
Below half Biotechnology median of 0.00%. Jim Chanos sees potential underinvestment or forced liquidation vs. peers.
-7.46%
Above 1.5x Biotechnology median of -2.48%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
8.60%
1.25-1.5x Biotechnology median 6.80%. Guy Spier is cautious about higher net leverage vs. median.
